scholarly journals Diagnosis of Tick-Borne Encephalitis by a  -Capture Immunoglobulin M-Enzyme Immunoassay Based on Secreted Recombinant Antigen Produced in Insect Cells

2003 ◽  
Vol 41 (9) ◽  
pp. 4336-4342 ◽  
Author(s):  
A. Jaaskelainen ◽  
X. Han ◽  
M. Niedrig ◽  
A. Vaheri ◽  
O. Vapalahti
Keyword(s):  
Enzyme Immunoassay ◽  
Insect Cells ◽  
Recombinant Antigen ◽  
Immunoglobulin M ◽  
Tick Borne Encephalitis

scholarly journals Detection of Norwalk Virus and Other Genogroup 1 Human Caliciviruses by a Monoclonal Antibody, RecombinantAntigen-Based Immunoglobulin M Capture Enzyme Immunoassay

1998 ◽  
Vol 36 (4) ◽  
pp. 1064-1069 ◽  
Author(s):  
James P. Brinker ◽  
Neil R. Blacklow ◽  
Mary K. Estes ◽  
Christine L. Moe ◽  
Kellogg J. Schwab ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Enzyme Immunoassay ◽  
Acute Phase ◽  
Recombinant Antigen ◽  
Immunoglobulin M ◽  
Norwalk Virus ◽  
Healthy Individuals ◽  
Test Specificity ◽  
Stool Samples ◽  
Adult Volunteers

Sera obtained from two groups of adult volunteers infected with Norwalk virus (NV) and two groups of patients involved in two natural outbreaks were tested for NV-reactive immunoglobulin M (IgM) by use of a monoclonal antibody, recombinant-antigen-based IgM capture enzyme immunoassay (EIA). No NV-reactive IgM was detected in the preinoculation sera of 15 volunteers, and 14 of 15 showed NV-reactive antibodies postinfection with NV. All of the volunteers showed IgG seroconversion to NV. In the outbreak studies, all 9 persons in one outbreak and 19 of 24 in another outbreak had NV-reactive IgM. In the first outbreak, only three of nine seroconverted to NV, which was likely due to late collection of acute-phase sera. In the second outbreak, 21 of 24 showed IgG seroconversion to NV. Sequencing of viruses isolated from five stool samples selected from those in the second outbreak showed that they were human calicivirus (HuCV) genogroup 1 viruses related, but not identical, to NV. In the volunteer studies, NV-reactive IgM was first detected 8 days postinoculation. The time of development of NV-reactive IgM antibodies in natural outbreaks was estimated to be similar to that found in the volunteer studies. Sera from three Hawaii virus-infected volunteers, four Snow Mountain virus patients, and 80 healthy individuals were negative for NV-reactive IgM, indicating test specificity for HuCV genogroup I infections. This capture IgM EIA is suitable for diagnosis of NV and other HuCV genogroup I infections and is especially useful when sera and fecal samples have not been collected early in the course of an outbreak.

TBE in Sweden

2020 ◽  
Keyword(s):  
Genetic Characterization ◽  
Immunoglobulin M ◽  
Enzyme Linked Immunosorbent Assay ◽  
Second Phase ◽  
Serum Samples ◽  
Tick Borne Encephalitis ◽  
Specific Immunoglobulin ◽  
Tick Borne Encephalitis Virus ◽  
First Time

Tick-borne encephalitis virus (TBEV) was isolated for the first time in Sweden in 1958 (from ticks and from 1 tick-borne encephalitis [TBE] patient).1 In 2003, Haglund and colleagues reported the isolation and antigenic and genetic characterization of 14 TBEV strains from Swedish patients (samples collected 1991–1994).2 The first serum sample, from which TBEV was isolated, was obtained 2–10 days after onset of disease and found to be negative for anti-TBEV immunoglobulin M (IgM) by enzyme-linked immunosorbent assay (ELISA), whereas TBEV-specific IgM (and TBEV-specific immunoglobulin G/cerebrospinal fluid [IgG/CSF] activity) was demonstrated in later serum samples taken during the second phase of the disease.

scholarly journals West Nile Virus Recombinant DNA Vaccine Protects Mouse and Horse from Virus Challenge and Expresses In Vitro a Noninfectious Recombinant Antigen That Can Be Used in Enzyme-Linked Immunosorbent Assays

2001 ◽  
Vol 75 (9) ◽  
pp. 4040-4047 ◽  
Author(s):  
Brent S. Davis ◽  
Gwong-Jen J. Chang ◽  
Bruce Cropp ◽  
John T. Roehrig ◽  
Denise A. Martin ◽  
...  
Keyword(s):  
United States ◽  
Recombinant Plasmid ◽  
Animal Health ◽  
The United States ◽  
Virus Antigen ◽  
Recombinant Antigen ◽  
Immunoglobulin M ◽  
E Proteins ◽  
West Nile ◽  
Immunosorbent Assays

ABSTRACT Introduction of West Nile (WN) virus into the United States in 1999 created major human and animal health concerns. Currently, no human or veterinary vaccine is available to prevent WN viral infection, and mosquito control is the only practical strategy to combat the spread of disease. Starting with a previously designed eukaryotic expression vector, we constructed a recombinant plasmid (pCBWN) that expressed the WN virus prM and E proteins. A single intramuscular injection of pCBWN DNA induced protective immunity, preventing WN virus infection in mice and horses. Recombinant plasmid-transformed COS-1 cells expressed and secreted high levels of WN virus prM and E proteins into the culture medium. The medium was treated with polyethylene glycol to concentrate proteins. The resultant, containing high-titered recombinant WN virus antigen, proved to be an excellent alternative to the more traditional suckling-mouse brain WN virus antigen used in the immunoglobulin M (IgM) antibody-capture and indirect IgG enzyme-linked immunosorbent assays. This recombinant antigen has great potential to become the antigen of choice and will facilitate the standardization of reagents and implementation of WN virus surveillance in the United States and elsewhere.

Unilateral associated laryngeal paralysis due to varicella-zoster virus: virus antibody testing and videofluoroscopic findings

2007 ◽  
Vol 122 (2) ◽  
pp. 170-176 ◽  
Author(s):  
S-I Chitose ◽  
H Umeno ◽  
S Hamakawa ◽  
T Nakashima ◽  
H Shoji
Keyword(s):  
Varicella Zoster Virus ◽  
Enzyme Immunoassay ◽  
Antiviral Therapy ◽  
Immunoglobulin M ◽  
Virus Antibody ◽  
Antibody Testing ◽  
Laryngeal Elevation ◽  
Pharyngeal Wall ◽  
Varicella Zoster ◽  
Laryngeal Paralysis

AbstractThe relationship between varicella-zoster virus and idiopathic associated laryngeal paralysis was examined in five patients, using complement fixation or enzyme immunoassay testing. In all cases, significant changes in serum levels of varicella-zoster virus antibody were observed. Videofluoroscopy was useful in assessing the severity of the dysphagia and in making an accurate diagnosis; both laryngeal elevation and weakness of pharyngeal wall contraction were also observed. In two cases in which antiviral therapy was delayed, the outcome was poor, with increased levels of varicella-zoster virus immunoglobulin M found on enzyme immunoassay. The outcome of the condition may thus depend both on the speed of antiviral therapy commencement following onset of symptoms, and on the levels of varicella-zoster virus immunoglobulin M antibody (measured by enzyme immunoassay). Our study suggests that varicella-zoster virus should be considered in the differential diagnosis of patients with idiopathic associated laryngeal paralysis, and rapid antiviral therapy should be initiated when necessary.

scholarly journals Solid-phase enzyme immunoassay for immunoglobulin M antibodies to cytomegalovirus

1977 ◽  
Vol 5 (6) ◽  
pp. 629-634
Author(s):  
H Schmitz ◽  
H W Doerr ◽  
D Kampa ◽  
A Vogt
Keyword(s):  
Alkaline Phosphatase ◽  
Horseradish Peroxidase ◽  
Enzyme Immunoassay ◽  
Indirect Immunofluorescence ◽  
Solid Phase ◽  
Immunoglobulin M ◽  
Nuclear Antigen ◽  
Immunofluorescence Method ◽  
Infected Cells

A sensitive, solid-phase enzyme immunoassay for the detection of immunoglobulin M antibodies to cytomegalovirus is described. The results of the enzyme immunoassay correlated well with those obtained by an indirect immunofluorescence method. Horseradish peroxidase proved to be a more sensitive label than alkaline phosphatase. Nonspecific reactions, occurring with commercially available cytomegalovirus antigens, could be avoided by using a nuclear antigen prepared from sonically disrupted nuclei of cytomegalovirus-infected cells.

Sign in / Sign up

Export Citation Format

Share Document